16. The use of claim 15, wherein the enhanced immune response comprises an enhanced antibody response, an enhanced T cell response or both.

17. The use of any one of claims 15-16, wherein the vaccine vector is to be administered by a route selected from the group consisting of oral, mucosal, parenteral, sub-cutaneous, intramuscular, intraocular and *in ovo*.

18. The use of any one of claims 15-17, wherein the subject is a poultry species or a mammal.

19. The use of claim 18, wherein the subject is selected from the group consisting of a human, swine, chicken, turkey and cow.

20. The use of any one of claims 15-19, wherein about 10^4 to about 10^9 vector copies of the vaccine are to be administered to the subject.

21. The use of any one of claims 15-20, wherein the vaccine vector is killed prior to administration to the subject or is not capable of replicating in the subject.

22. The use of any one of claims 15-21, wherein the Apicomplexan parasite is selected from the group consisting of *Eimeria, Plasmodium, Toxoplasma*, *Neospora* and *Cryptosporidium*.

23. The vaccine vector of any one of claims 1-12, wherein the Rhomboid polypeptide consists of SEQ ID NO: 2.

24. The vaccine vector of any one of claims 1-12, wherein the Rhomboid polypeptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 37, or SEQ ID NO: 38.